Promising new combo targets rare leukemia in early trial
NCT ID NCT07573670
First seen May 14, 2026 · Last updated May 14, 2026
Summary
This study tests a combination of two or three drugs (Bcl-2 inhibitor, azacitidine, and possibly blinatumomab) in people newly diagnosed with a rare and aggressive leukemia called mixed phenotype acute leukemia (MPAL). The goal is to see if this treatment can lead to complete remission and allow patients to proceed to a stem cell transplant. About 52 participants aged 16 to 70 will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED MIXED PHENOTYPE ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000, China
Conditions
Explore the condition pages connected to this study.